Nuvectis Pharma (NVCT) Earnings Call Presentation

Company Overview - Nuvectis Pharma focuses on precision medicine for oncology with unmet medical needs[6] - The company has ongoing clinical trials for NXP800 and NXP900[6] - Management team has a track record with 3 approved drugs in 4 indications in the US and EU[6] - The company's cash runway extends into 2027[6] NXP800 - NXP800 shows substantial antitumor activity in ARID1a-mutated ovarian carcinoma xenografts[13] - Clinical data from the Phase 1b trial shows antitumor activity, including one patient with an unconfirmed partial response and six patients with stable disease[17] - NXP800 targets cancers with ARID1a mutations, with an estimated 2,300 ovarian cancer patients, 23,600 endometrial carcinoma patients, 1,400 cholangiocarcinoma patients, 25,600 urothelial cancer patients, 9,070 hepatocellular cancer patients, and 6,600 gastric cancer patients in the US[18] NXP900 - NXP900 is a potent, novel, small molecule inhibitor of YES1/SRC signaling[21] - NXP900 achieves approximately 90% inhibition of SRC autophosphorylation (pSRC) after a single dose at doses ≥150 mg/day[33] - NXP900 is being evaluated in a Phase 1a dose escalation clinical trial[21]